BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program
March 10 2022 - 8:00AM
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”)
(NASDAQ:
BRTX), a clinical stage company focused
on stem cell-based therapies, today announced that it has entered
into a research collaboration agreement with Dr. Tore Bengtsson,
Professor of the Department of Molecular Biosciences, at the
Wenner-Gren Institute, at Stockholm University.
The research is intended to advance the
Company’s understanding of the biology and role of brown fat tissue
in the ability to produce heat. The proposed research involves
studying BioRestorative’s proprietary cell-lines, both primary
adipose cells and brown adipocyte cells differentiated in culture,
and their thermogenic response.
“We are excited to enter into this research
collaboration with Professor Bengtsson’s laboratory. Heat
production is an important biological property of ThermoStem® and
understanding its role may expand our platform technology.” said
Francisco Silva, the Company’s Vice President of Research and
Development.
Professor Bengtsson’s laboratory has pioneered
research on brown adipose biology and its impact on metabolic
disease. He recently published a study
(https://www.nature.com/articles/s42003-021-02639-4) demonstrating
the use of isothermal microcalorimetry as a sensitive and accurate
technique for measuring thermogenic responses in intact mature
brite adipocytes.
Professor Bengtsson is also co-founder of Atrogi
and Sigrid Therapeutics, two clinical stage companies. Atrogi is
developing a novel small molecule for treating type 2 diabetes and
Sigrid Therapeutics is developing engineered micron-sized silica
particles designed to act locally in the gut to reduce blood sugar
levels in people at risk of developing type 2 diabetes.
“Beneficial and substantial heat production is a
unique property few cells are capable of generating. We look
forward to understanding its role and impact on BioRestorative’s
ThermoStem® program,” said Professor Bengtsson.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process utilizes
proprietary technology and involves collecting a patient’s bone
marrow, isolating and culturing stem cells from the bone marrow and
cryopreserving the cells. In an outpatient procedure, BRTX-100 is
to be injected by a physician into the patient’s damaged disc. The
treatment is intended for patients whose pain has not been
alleviated by non-invasive procedures and who potentially face the
prospect of surgery. We have received authorization from the Food
and Drug Administration to commence a Phase 2 clinical trial using
BRTX-100 to treat chronic lower back pain arising from degenerative
disc disease.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024